Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
نویسندگان
چکیده
The British Society for Paediatric and Adolescent Rheumatology (BSPAR) Biologics Register monitors JIA patients treated with etanercept +/methotrexate. We report duration of etanercept use and reasons for discontinuation, defined as cessation due to disease control or treatment failure; not including precautionary or temporary drug discontinuation for transient adverse events. KaplanMeier survival analysis was conducted with remaining patients censored at five years follow-up.
منابع مشابه
Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
OBJECTIVE Since 2004, juvenile idiopathic arthritis (JIA) patients treated with etanercept and/or MTX have been monitored in the British Society for Paediatric and Adolescent Rheumatology Biologics and New Drug Register. Here, we report the duration of etanercept use for the first 5 years of the register and reasons for discontinuation. METHODS Disease subtype and activity, comorbidity, treat...
متن کاملSwitching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis
Results A total of 33 patients initially treated with Etanercept were switched to Adalimumab after a mean of 25.9 months (range 3–87 months). Reasons for discontinuation of Etanercept were inefficacy (n = 23, 65.8%), uveitis (n = 6, 17.1%), intolerance (n = 3, 8.6%) and patients' request (n = 6, 17.1%). Follow up data on Adalimumab were obtained from 12 patients for a range of 2 to 26 months (m...
متن کاملFactors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
OBJECTIVES The objectives of this study were to investigate change in disease activity, and explore factors associated with response, in children with JIA over the initial year of etanercept treatment. METHODS This analysis included children with JIA starting etanercept in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Response was assessed using chang...
متن کاملEffect of etanercept on refractory systemic-onset juvenile idiopathic arthritis.
BACKGROUND Treatment of systemic-onset juvenile idiopathic arthritis (So-JIA) is challenging, and the efficacy of injectable recombinant human tumor necrosis factor type 1 receptor-antibody fusion protein (etanercept) on So-JIA has been controversial. METHODS We retrospectively studied 12 patients with refractory systemic juvenile arthritis treated with etanercept at our hospital in the past ...
متن کامل[Duration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic disease].
OBJECTIVE To evaluate the duration of etanercept (ETN) treatment and motives for discontinuation in our local cohort of patients with rheumatic pathology and compare them to the group with other biological treatments. PATIENTS AND METHODS Prospective observational cohort study. Disease diagnosis, start and end date and motive for discontinuation were recorded. Survival estimation was explored...
متن کامل